See more : PTG Energy Public Company Limited (PTG-R.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Silence Therapeutics plc (SLN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Silence Therapeutics plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Contango Ore, Inc. (CTGO) Income Statement Analysis – Financial Results
- Rajoo Engineers Limited (RAJOOENG.BO) Income Statement Analysis – Financial Results
- First Midwest Bancorp, Inc. (FMBIP) Income Statement Analysis – Financial Results
- Guoguang Electric Company Limited (002045.SZ) Income Statement Analysis – Financial Results
- Hsin Tai Gas Co., Ltd. (8917.TWO) Income Statement Analysis – Financial Results
Silence Therapeutics plc (SLN)
About Silence Therapeutics plc
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.38M | 17.50M | 12.42M | 5.48M | 244.00K | 0.00 | 16.00K | 770.00K | 0.00 | 15.00K | 117.00K | 163.00K | 694.00K | 2.37M | 1.72M | 2.21M | 4.05M | 1.95M | 509.00K | 159.00K | 1.34M | 1.15M | 138.00K | 959.00K | 1.37M | 210.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 10.32M | 10.88M | 7.46M | 3.76M | 0.00 | 9.74M | 7.94M | 8.71M | 7.11M | 8.88M | 5.65M | 3.38M | 3.36M | 5.82M | 5.07M | 6.71M | 4.84M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 15.06M | 6.62M | 4.96M | 1.72M | 244.00K | -9.74M | -7.93M | -7.94M | -7.11M | -8.87M | -5.53M | -3.22M | -2.67M | -3.46M | -3.35M | -4.50M | -796.00K | 1.95M | 509.00K | 159.00K | 1.34M | 1.15M | 138.00K | 959.00K | 1.37M | 210.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 59.34% | 37.83% | 39.94% | 31.34% | 100.00% | 0.00% | -49,543.75% | -1,031.30% | 0.00% | -59,126.67% | -4,727.35% | -1,972.39% | -384.29% | -146.03% | -194.43% | -203.85% | -19.67% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 44.03M | 35.61M | 30.77M | 20.21M | 13.34M | 9.74M | 7.94M | 8.71M | 7.11M | 8.88M | 5.65M | 3.38M | 3.36M | 5.82M | 5.07M | 6.71M | 4.84M | 3.19M | 1.66M | 1.70M | 3.01M | 2.46M | 2.49M | 3.00M | 3.05M | 1.68M | 1.83M | 986.00K | 790.00K |
| General & Administrative | 20.64M | 19.61M | 20.01M | 13.98M | 9.64M | 10.83M | 6.46M | 3.97M | 2.66M | 3.26M | 3.54M | 2.61M | 2.65M | 5.13M | 3.19M | 3.29M | 4.99M | 3.03M | 2.75M | 1.83M | 1.01M | 700.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.64M | 19.61M | 20.01M | 13.98M | 9.64M | 10.83M | 6.46M | 3.97M | 2.66M | 3.26M | 3.54M | 2.61M | 2.65M | 5.13M | 3.19M | 3.29M | 4.99M | 3.03M | 2.75M | 1.83M | 1.01M | 700.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 3.37M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -269.00K | 7.00K | -112.00K | -20.00K | 72.00K | -154.00K | -21.00K | 56.00K | -1.00K | -216.00K | -287.00K | 673.00K | 693.00K | 503.00K | 429.00K | 329.00K | 258.00K | 143.00K |
| Operating Expenses | 64.66M | 55.21M | 50.77M | 37.56M | 22.98M | 20.57M | 14.41M | 12.68M | 9.77M | 12.14M | 9.19M | 5.99M | 2.65M | 5.13M | 4.18M | 3.29M | 4.84M | 6.21M | 4.40M | 3.53M | 4.02M | 3.16M | 3.17M | 3.69M | 3.55M | 2.11M | 2.16M | 1.24M | 933.00K |
| Cost & Expenses | 74.98M | 66.09M | 58.23M | 41.33M | 22.98M | 20.57M | 14.41M | 12.68M | 9.77M | 12.14M | 9.19M | 5.99M | 6.01M | 10.95M | 9.26M | 10.00M | 9.68M | 6.21M | 4.40M | 3.53M | 4.02M | 3.16M | 3.17M | 3.69M | 3.55M | 2.11M | 2.16M | 1.24M | 933.00K |
| Interest Income | 1.45M | 226.00K | 10.00K | 129.00K | 27.00K | 39.00K | 206.00K | 1.54M | 175.00K | 147.00K | 70.00K | 18.00K | 56.00K | 95.00K | 46.00K | 357.00K | 544.00K | 348.00K | 264.00K | 133.00K | 216.00K | 317.00K | 522.00K | 505.00K | 163.00K | 324.00K | 398.00K | 279.00K | 59.00K |
| Interest Expense | 34.00K | 47.00K | 8.00K | 323.00K | 163.00K | 0.00 | 15.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.00K | 63.00K | 0.00 | -31.00K | 0.00 | 20.00K | 1.00K | 71.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -398.00K | -279.00K | -59.00K |
| Depreciation & Amortization | 498.00K | 482.00K | 427.00K | 496.00K | 482.00K | 399.00K | 433.00K | 310.00K | 182.00K | 332.00K | 297.00K | 252.00K | 305.00K | 323.00K | 371.00K | 423.00K | 318.00K | 353.00K | 216.00K | 38.00K | 44.00K | 56.00K | 42.00K | 29.00K | 6.00K | 36.00K | 34.00K | 34.00K | 1.00K |
| EBITDA | -49.78M | -47.89M | -45.42M | -35.53M | -22.36M | -20.17M | -3.33M | -11.60M | -9.59M | -11.80M | -8.78M | -5.31M | -5.42M | -8.17M | -7.12M | -7.44M | -5.32M | -3.59M | -3.42M | -3.20M | -2.63M | -1.95M | -2.99M | -2.71M | -2.17M | -1.87M | -2.13M | -1.21M | -932.00K |
| EBITDA Ratio | -196.17% | -273.61% | -365.50% | -642.85% | -9,108.61% | 0.00% | -208,962.50% | -1,505.97% | 0.00% | -78,633.33% | -7,500.00% | -3,409.82% | -713.69% | -345.31% | -413.06% | -317.43% | -117.91% | -183.10% | -669.94% | -2,010.06% | -179.54% | -143.09% | -2,163.04% | -282.17% | -158.61% | -889.05% | 0.00% | 0.00% | 0.00% |
| Operating Income | -49.60M | -48.59M | -45.81M | -35.85M | -22.73M | -20.57M | -14.39M | -11.91M | -9.77M | -12.13M | -9.07M | -26.31M | -5.79M | -8.66M | -7.55M | -7.79M | -5.79M | -4.27M | -3.90M | -3.37M | -2.67M | -2.01M | -3.03M | -2.74M | -2.18M | -1.90M | -2.16M | -1.24M | -933.00K |
| Operating Income Ratio | -195.48% | -277.66% | -369.02% | -654.26% | -9,317.21% | 0.00% | -89,943.75% | -1,546.23% | 0.00% | -80,846.67% | -7,753.85% | -16,143.56% | -833.72% | -365.93% | -438.42% | -352.74% | -143.02% | -219.21% | -765.82% | -2,118.24% | -198.88% | -174.20% | -2,193.48% | -285.19% | -159.05% | -906.19% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -706.00K | 1.23M | -42.00K | -194.00K | -136.00K | 45.00K | 10.62M | 1.54M | 340.00K | 147.00K | 70.00K | -20.46M | 49.00K | -137.00K | 46.00K | 357.00K | 544.00K | 328.00K | 263.00K | 62.00K | 216.00K | 302.00K | 479.00K | 505.00K | 163.00K | 324.00K | 398.00K | 279.00K | 59.00K |
| Income Before Tax | -50.31M | -47.37M | -45.86M | -36.04M | -22.87M | -20.53M | -3.78M | -10.36M | -9.43M | -11.98M | -9.00M | -26.28M | -5.74M | -8.80M | -7.51M | -7.44M | -5.24M | -3.94M | -3.64M | -3.31M | -2.46M | -1.70M | -2.55M | -2.23M | -2.02M | -1.58M | -1.76M | -965.00K | -874.00K |
| Income Before Tax Ratio | -198.27% | -270.66% | -369.36% | -657.80% | -9,372.95% | 0.00% | -23,593.75% | -1,345.71% | 0.00% | -79,866.67% | -7,694.02% | -16,125.15% | -826.66% | -371.72% | -435.75% | -336.58% | -129.58% | -202.36% | -714.15% | -2,079.25% | -182.81% | -147.96% | -1,846.38% | -232.53% | -147.15% | -751.90% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -7.04M | -6.88M | -6.45M | -3.49M | -3.29M | -2.12M | -2.16M | -1.92M | -2.78M | -892.00K | -70.00K | -30.00K | -49.00K | 137.00K | -37.00K | -357.00K | -136.00K | -114.00K | -50.00K | -350.00K | -177.00K | -220.00K | -354.00K | -286.00K | 124.00K | -324.00K | -398.00K | -279.00K | -59.00K |
| Net Income | -43.27M | -40.49M | -39.41M | -32.55M | -19.58M | -18.41M | -1.62M | -8.44M | -6.65M | -11.09M | -9.00M | -26.28M | -5.74M | -8.80M | -7.47M | -7.44M | -5.11M | -3.83M | -3.59M | -2.96M | -2.28M | -1.48M | -2.19M | -1.94M | -2.14M | -1.58M | -1.76M | -965.00K | -874.00K |
| Net Income Ratio | -170.51% | -231.35% | -317.44% | -594.03% | -8,025.41% | 0.00% | -10,112.50% | -1,096.10% | 0.00% | -73,920.00% | -7,694.02% | -16,125.15% | -826.66% | -371.72% | -433.60% | -336.58% | -126.22% | -196.51% | -704.32% | -1,859.12% | -169.64% | -128.84% | -1,589.86% | -202.71% | -156.20% | -751.90% | 0.00% | 0.00% | 0.00% |
| EPS | -1.17 | -1.26 | -1.33 | -1.19 | -0.78 | -0.79 | -0.07 | -0.36 | -0.31 | -0.66 | -0.61 | -4.11 | -1.84 | -4.74 | -8.32 | -9.30 | -6.59 | -6.03 | -8.83 | -18.57 | -14.33 | -9.32 | -13.79 | -12.77 | -15.59 | -12.00 | -13.68 | -7.59 | -7.95 |
| EPS Diluted | -1.17 | -1.26 | -1.33 | -1.19 | -0.78 | -0.79 | -0.07 | -0.36 | -0.31 | -0.66 | -0.61 | -4.11 | -1.84 | -4.74 | -8.32 | -9.30 | -6.59 | -6.03 | -8.83 | -18.57 | -14.33 | -9.32 | -13.79 | -12.77 | -15.59 | -12.00 | -13.68 | -7.59 | -7.95 |
| Weighted Avg Shares Out | 37.09M | 32.19M | 29.65M | 27.26M | 25.04M | 23.44M | 23.31M | 23.27M | 21.34M | 16.81M | 14.64M | 6.39M | 3.11M | 1.86M | 897.60K | 799.24K | 775.31K | 634.26K | 405.84K | 159.15K | 159.07K | 159.07K | 159.07K | 152.23K | 137.25K | 131.57K | 128.69K | 127.20K | 109.93K |
| Weighted Avg Shares Out (Dil) | 37.09M | 32.19M | 29.65M | 27.26M | 25.04M | 23.44M | 23.31M | 23.27M | 21.34M | 16.81M | 14.64M | 6.39M | 3.11M | 1.86M | 897.60K | 799.24K | 775.31K | 634.26K | 405.84K | 159.15K | 159.07K | 159.07K | 159.07K | 152.23K | 137.25K | 131.57K | 128.69K | 127.20K | 109.93K |
Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), a global clinical stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat...
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels
Silence Therapeutics stock falls despite lowering lipoprotein levels in a phase II study of zerlasiran likely due to concerns regarding its competitive profile.
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
On Monday, Silence Therapeutics plc SLN presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 nmol/L).
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), a global clinical stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today presented end-of-treatment data from its Phase 2 ALPACAR-360 study...
Silence Therapeutics' RNAi Pipeline: Zerlasiran's Game-Changer Potential Is A 'Buy'
Silence Therapeutics focuses on RNA interference therapies, with its lead candidates targeting cardiovascular and hematological diseases via the mRNAi GOLD platform. Zerlasiran, the company's main value driver, aims to reduce lipoprotein(a) levels, potentially lowering cardiovascular risks in 20-25% of the...
Silence: Additional siRNA Drug Data Leads To Next Stages Of Development
Silence Therapeutics plc's positive results achieved from phase 1 SANRECO study using divesiran for the treatment of patients with polycythemia vera. The global polycythemia vera treatment market size is predicted to reach $45 billion by the end of 2036. Full...
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced that management will present company overviews at the...
The 3 Best Gene Editing Stocks to Buy in August 2024
Investing guru Cathie Wood sees precision therapeutics as a massive growth market. She forecasts sales in the category can grow by a compound annual growth rate (CAGR) of 30% through 2030.
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
Wall Street likes to peer into the fog of the future and guess where a stock is headed. While these stock price predictions are based on educated estimates, often based on information and models unavailable to regular investors, they are...
Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last?
Silence Therapeutics (SLN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Source: https://incomestatements.info
Category: Stock Reports